Filing Details

Accession Number:
0001104659-19-043306
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-08-01 14:49:49
Reporting Period:
2019-07-31
Accepted Time:
2019-08-01 14:49:49
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
886163 Ligand Pharmaceuticals Inc LGND Pharmaceutical Preparations (2834) 770160744
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1442372 L Stephen Sabba Dorset Management Corp
485 Underhill Blvd Suite 205
Syosset NY 11791
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2019-07-31 4,091 $94.45 23,600 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. These securities, as represented in Column 5, include restricted shares comprised of: (a) a grant of 835 restricted shares in a transaction exempt from Section 16b treatment, as originally reported on a Form 4 filed June 10, 2019, which shares will vest in full on the earlier of (i) the date of the next annual meeting of the Company stockholders following the grant date or (ii) on the first anniversary of the grant date; and (b) fully vested restricted shares granted in respective transactions, each exempt from Section 16b treatment and reported on previously filed Form 4s for the Reporting Person.
  2. The price reported is based on an average share price from the following transactions: ((767 shares @ $96.0691)+(100 shares @ $95.605)+(600 shares @ $95.438334)+(2,624 shares @ $93.70))/ 4,091 shares. The price reported has been rounded from $94.4456857 for formatting purposes.